Single Oral Dose Escalation Study of DNDI-0690 in Healthy Subjects

NCT03929016 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

64

Enrollment

OTHER

Sponsor class

Conditions

Visceral Leishmaniasis
Cutaneous Leishmaniases

Interventions

DRUG: DNDI-0690
DRUG: Placebo of DNDI-0690

Sponsor

Drugs for Neglected Diseases

Collaborators

[object Object]